Clinical Data

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

PharmaTimes

Latebreaking EULAR results highlight sustained responses through week 52

Immunology & Inflammation

Read full story

pharminent June 4, 2026 (Last updated: June 4, 2026)

PharmaTimes

Latebreaking EULAR results highlight sustained responses through week 52

Immunology & Inflammation

Read full story